Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension

被引：0
|
作者：
Soelberg-Sorensen, P. [1 ]
Dangond, F. [2 ]
Hicking, C. [3 ]
Giovannoni, G. [4 ]
机构：
[1] Univ Copenhagen, Rigshosp, Dept Neurol, Copenhagen, Denmark
[2] EMD Serono Inc, Billerica, MA USA
[3] Merck KGaA, Darmstadt, Germany
[4] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1141
引用
收藏
页码：598 / 599
页数：2
相关论文
共 50 条
  • [1] Innate immune cell counts in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) treated with cladribine tablets 3.5mg/kg in CLARITY and CLARITY extension
    Soelberg-Sorensen, P.
    Dangond, F.
    Hicking, C.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 528 - 528
  • [2] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
    Soelberg-Sorensen, Per
    Dangond, Fernando
    Hicking, Christine
    Giovannoni, Gavin
    NEUROLOGY, 2017, 88
  • [3] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
    Soelberg-Sorensen, Per
    Dangond, Fernando
    Hicking, Christine
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP12 - NP12
  • [4] Absolute lymphocyte counts in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5 mg/kg in the CLARITY and CLARITY Extension studies
    Soelberg-Sorensen, P.
    Dangond, F.
    Hicking, C.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 412 - 412
  • [5] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensen, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP7
  • [6] Efficacy of cladribine tablets 3.5 mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; clarity and clarity extension
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Keller, B.
    di Cantogno, E. Verdun
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [7] Effectiveness Of Cladribine Tablets In Patients With Relapsing-remitting Multiple Sclerosis With Baseline EDSS ≥3.5 Or ≤3.0 In CLARITY
    Comi, G.
    Pardo, G.
    Dangond, F.
    Aldridge, J.
    Lemieux, C.
    Rammohan, K.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 42 - 43
  • [8] Efficacy of cladribine tablets 3.5 mg/kg in patients ≤50 and >50 years of age with relapsing-remitting multiple sclerosis (RRMS): a post hoc analysis from CLARITY
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Dangond, F.
    Damian, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 331 - 331
  • [9] Efficacy of cladribine tablets 3.5mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; CLARITY and CLARITY Extension
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Keller, B.
    Di Cantogno, E. Verdun
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 492 - 492
  • [10] Severity and frequency of relapses in patients with relapsing-remitting MS treated with cladribine tablets in CLARITY and placebo in CLARITY extension
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    Dangond, F.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 857 - 858
12345